MK-677

MK-677, also known as ibutamoren, is a non-peptide molecule that works by activating the ghrelin receptor (GHSR1a), the same receptor targeted by the hunger hormone ghrelin Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1. Unlike injectable peptide secretagogues, it is orally active and produces a sustained increase in growth hormone (GH) and insulin-like growth factor-1 (IGF-1) over about 24 hours after a single dose Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects+1.

It was developed to amplify the body's own GH axis without needing injections, and early human studies in the 1990s showed robust GH and IGF-1 responses in older adults and adults with partial GH deficiency Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects+1. Later trials explored its potential for preserving muscle in catabolic states, aiding recovery after hip fracture, and modifying body composition MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study+2.

Today, MK-677 is not approved for any medical indication, but it remains a research compound and is sometimes encountered in gray-market performance-enhancement products Development of pharmacological interventions for the treatment of sarcopenia+2. The research evidence is strongest for endocrine effects (raising GH/IGF-1) and modest lean mass changes, while functional outcomes and disease-specific benefits are less consistent Development of pharmacological interventions for the treatment of sarcopenia+2.

MK-677 binds to and activates the ghrelin receptor (GHSR1a) on cells in the pituitary gland and elsewhere Beyond Hunger: The Structure, Signaling, and Systemic Roles of Ghrelin+1. This activation tells the pituitary to release more growth hormone, but in a pulsatile pattern that mimics natural secretion rather than a constant flood Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects+1. Once released, GH travels to the liver and other tissues to drive production of IGF-1, which mediates many of the anabolic effects Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1.

This receptor is also found in brain regions that control appetite, sleep, and stress responses, which explains why hunger, sleep architecture changes, and mood shifts are common side topics in research Beyond Hunger: The Structure, Signaling, and Systemic Roles of Ghrelin+1. The compound's long action means one daily dose can sustain elevated GH and IGF-1 throughout the day and night Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects+1.

Structural studies show ibutamoren fits snugly into the receptor's active pocket, engaging key amino acids that trigger intracellular signaling through G proteins and other pathways Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren. This receptor-level action is distinct from simply injecting growth hormone because it amplifies the body's own production while still allowing natural feedback regulation Beyond Hunger: The Structure, Signaling, and Systemic Roles of Ghrelin+1.

Growth hormone and IGF-1 elevation Multiple human studies confirm that daily oral MK-677 reliably increases GH secretion and serum IGF-1 levels in healthy older adults, GH-deficient adults, and other populations Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects+2. This is the most reproducible finding across all research.

Body composition changes In older adults, MK-677 increased fat-free mass, though changes were often modest and not always accompanied by functional gains; it has not been shown to reduce fat mass and may increase body weight through both lean and fat compartments Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults+2. The anabolic signal is present, but translating it into meaningful strength or mobility improvements has been inconsistent Development of pharmacological interventions for the treatment of sarcopenia+1.

Appetite increase As a ghrelin receptor agonist, MK-677 strongly stimulates appetite. This effect is central to its weight-gain profile and is often noted in studies of catabolic conditions, but it can be a drawback in other settings Beyond Hunger: The Structure, Signaling, and Systemic Roles of Ghrelin+1.

Sleep modulation In healthy volunteers, longer-term MK-677 treatment increased deep (stage IV) and REM sleep and reduced sleep abnormalities, an effect tied to ghrelin's role in sleep regulation Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man.

Negative effects observed Common research-reported side effects include fluid retention (edema, bloating), transient insulin resistance (elevated fasting glucose), and lethargy Development of pharmacological interventions for the treatment of sarcopenia+2. A hip-fracture trial was stopped early due to a safety signal of congestive heart failure, though this occurred in a frail population MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Recent case reports have raised concerns about liver toxicity and a case of atraumatic splenic rupture in a user taking multiple performance-enhancing compounds, including MK-677 Hepatotoxicity induced by MK-677+1. It's important to note that many real-world adverse events are confounded by product contamination or stacking with other drugs Reversible Gynecomastia and Hypogonadism Due to Usage of Commercial Performance-Enhancing Supplement Use+2.

Research protocols for MK-677 are exclusively oral, as it was designed as an orally active compound Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+2. Community protocols commonly use 10-25 mg once daily (human trial doses are not clearly defined in the reviewed literature) Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults+3.

A representative protocol used in many studies begins with a 2-week titration at 10 mg/day to assess tolerability, then increases to 25 mg/day for the remainder of the study period, which often lasts 8-16 weeks Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults+1. Blood draws for IGF-1, fasting glucose, and liver enzymes are typically done at baseline and at intervals during the study.

Timing is usually at night to align with natural GH release and to manage daytime appetite Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Research groups often monitor body weight, edema, blood pressure, and glucose regularly because of known fluid-retention and insulin-sensitivity risks Development of pharmacological interventions for the treatment of sarcopenia+1.

Cycling is not mandated by receptor desensitization evidence, but periodic breaks are common in research designs to limit cumulative side effects like edema or glucose dysregulation Development of pharmacological interventions for the treatment of sarcopenia+2.

MK-677 is a small-molecule oral agent, not a lyophilized peptide needing reconstitution for injection Development of pharmacological interventions for the treatment of sarcopenia+1. In all published human trials, it was administered orally in capsule or solution form Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects+2.

If a research supplier provides a dry powder in a vial, it is important to understand that reconstitution for injection is not a validated clinical route and may introduce safety risks. For oral use, the powder is typically dissolved in a small amount of water or directly measured and consumed, but this approach lacks standardization.

The compound is chemically stable and does not require the same sterile handling as injectable peptides, but proper storage in a dry, cool environment is still recommended to preserve potency Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

MK-677 interacts with several classes of compounds due to its effects on the GH/IGF-1 axis, appetite, and fluid balance.

Glucose-lowering medications: Because MK-677 can impair insulin sensitivity and raise blood glucose, it may reduce the effectiveness of diabetes drugs like metformin, GLP-1 agonists, or insulin Development of pharmacological interventions for the treatment of sarcopenia+2. Monitoring fasting glucose is essential when these are co-administered in research.

Other GH secretagogues or exogenous GH: Stacking MK-677 with compounds like CJC-1295, sermorelin, or injectable GH can amplify IGF-1 elevation and increase side-effect risk (edema, insulin resistance) without clear evidence of additive benefit Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1.

SARMs and anabolic steroids: Real-world surveillance shows that MK-677 is frequently found in products contaminated or deliberately mixed with SARMs or oral steroids Systematic review of undeclared prohibited substances and pharmacological adulterants in dietary supplements: prevalence, detection, and risks in sport+1. These combinations elevate liver toxicity and endocrine disruption risks beyond those of MK-677 alone Reversible Gynecomastia and Hypogonadism Due to Usage of Commercial Performance-Enhancing Supplement Use+1.

CNS-active agents: Animal research suggests MK-677 can reverse stress-suppressed feeding and interact with anxiety pathways, so additive sedation with benzodiazepines or alcohol is possible, though not well-studied in humans Acute stress suppresses hunger-driven food seeking through PVN activation: Reversal by anxiolytic drug and ghrelin receptor agonist, with anxiolytic-like effects of refeeding.

Drugs that affect fluid balance: The heart failure signal in a hip-fracture trial suggests caution with diuretics, RAAS blockers, and any condition predisposing to volume overload MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study.

Unlike some peptides that require frequent receptor resets, MK-677's cycling rationale is driven more by side-effect management than tachyphylaxis Growth hormone secretagogues as potential therapeutic agents to restore growth hormone secretion in older subjects to those observed in young adults. The compound's prolonged GH/IGF-1 elevation can lead to cumulative fluid retention, appetite escalation, and insulin resistance over weeks Development of pharmacological interventions for the treatment of sarcopenia+2.

Research designs often incorporate 8- to 16-week cycles with a 4-week washout to allow these parameters to normalize. There is no direct evidence that receptor desensitization occurs in humans to a degree that mandates cycling, but animal data suggest GH response may attenuate after chronic exposure Growth hormone secretagogues as potential therapeutic agents to restore growth hormone secretion in older subjects to those observed in young adults. Breaks also reduce the burden of continuous monitoring for glucose and liver changes Hepatotoxicity induced by MK-677.

MK-677 is often mentioned in the context of stacks with other compounds, though most combinations are not formally studied.

With BPC-157 / TB-500: Frequently seen in community recovery stacks, with no reported receptor conflict, though stacked complexity may confound side-effect attribution Injuries, Injections, and Internet Forums: A Qualitative Study of Reddit User Perspectives on Peptide Therapy After Orthopaedic Surgery.

With GHRP/GHRH peptides: Combining MK-677 (a ghrelin receptor agonist) with peptides that also stimulate GH release (like GHRP-2 or CJC-1295) is mechanistically redundant and likely to increase side effects without proportional benefit Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

With SARMs: The most common real-world stack, but highly risky due to product contamination, liver stress, and endocrine disruption Reversible Gynecomastia and Hypogonadism Due to Usage of Commercial Performance-Enhancing Supplement Use+2. Surveillance data suggest many purported MK-677 products already contain SARMs, so stacking adds uncertainty.

MK-677 is not approved by the FDA or any major regulatory agency for therapeutic use Development of pharmacological interventions for the treatment of sarcopenia+1. It is classified as an investigational compound and remains under study for various conditions, but there is no approved drug product available through legitimate prescribing channels.

It is prohibited in sport under WADA rules as a growth hormone secretagogue, and anti-doping laboratories actively test for it in urine and hair Systematic review of undeclared prohibited substances and pharmacological adulterants in dietary supplements: prevalence, detection, and risks in sport+2. Several countries have encountered it in illegal supplement and performance-enhancing product markets SARMs, Metabolic Modulators and Growth Hormone Secretagogues in Suspected Illegal Medicines, Bought as Sport Performance Enhancers: A Retro- and Prospective Study Within the GEON+1.

The safety profile of MK-677 is characterized by consistent endocrine activation and a range of common to rare adverse events.

Common research-reported effects include increased appetite, fluid retention with weight gain, transient insulin resistance (elevated fasting glucose), and lethargy Development of pharmacological interventions for the treatment of sarcopenia+2. These are typically dose-dependent and often manageable, but they require monitoring.

The most significant safety signal emerged in a hip-fracture trial, where a higher incidence of congestive heart failure led to early study termination, raising concerns about use in fluid-sensitive populations MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Isolated cases of reversible liver enzyme elevation and atraumatic splenic rupture have been reported, though the latter occurred in a user also taking a SARM Hepatotoxicity induced by MK-677+1.

The widespread problem of adulterated and mislabeled products adds a major layer of risk: many samples sold as MK-677 contain other undeclared drugs, including steroids and SARMs, which can cause hormone suppression and liver injury Systematic review of undeclared prohibited substances and pharmacological adulterants in dietary supplements: prevalence, detection, and risks in sport+1. For any research use, verifying the identity and purity of the compound is crucial.